Sunitinib Effective in Very Rare Neuroendocrine Tumor The TKI boosted PFS in patients with malignant pheochromocytoma and paraganglioma Sep 20, 2021
Chemo Plus Keytruda Boosts Overall Survival in Advanced TNBC KEYNOTE-355 regimen offers "transformative treatment" in PD-L1-positive disease, expert says Sep 20, 2021
ADC Makes a Case for Role in Metastatic HER2-Positive Breast Cancer Improved progression-free survival in previously treated disease with trastuzumab duocarmazine Sep 20, 2021
Combo Treatment Extends Survival in HR+HER2- Advanced Breast Cancer MONALEESA-2's "big message": 12.5-month boost in median OS with ribociclib-aromatase inhibitor Sep 19, 2021
Another Possible Option for HER2-Mutated Non-Small Cell Lung Cancer More than half of patients responded to antibody-drug conjugate targeting HER2 Sep 19, 2021
Adjuvant Pembrolizumab Boosts Recurrence-Free Survival in High-Risk Melanoma Also, fewer cases of distant recurrences in KEYNOTE-716 trial Sep 19, 2021
Practice-Changing Study in Advanced Cervical Cancer Improved PFS, OS with pembrolizumab and chemo with or without bevacizumab Sep 18, 2021
Trastuzumab Deruxtecan: New Standard of Care in Pretreated, Advanced Breast Cancer? DESTINY-Breast03 turns in "absolutely startling" PFS in HER2-positive metastatic disease Sep 18, 2021
Extended Letrozole Reduced Recurrence Risk in Postmenopausal Breast Cancer 5 years of the aromatase inhibitor improved disease-free survival vs 2-3 years Sep 17, 2021
Rechallenge With PARP Inhibitor Slows Relapsed Ovarian Cancer Benefits platinum-sensitive disease irrespective of BRCA, homologous repair status, study showed Sep 17, 2021
Cancer Patients, COVID-19, and Long-Term Effects Preventing COVID sequelae can minimize disruption of cancer care, European study finds Sep 09, 2021
Keytruda Before, After Surgery Improves Outcome in TNBC Results from KEYNOTE-522 show "practice-changing" impact on EFS Jul 15, 2021
Positive Anti-PD-1 Data in Gastric, Esophageal Cancer Better OS, PFS with nivolumab, pembrolizumab in advanced/metastatic disease Sep 23, 2020
Immunotherapy Falls Short Again in Ovarian Cancer No PFS benefit in advanced disease with addition of atezolizumab to chemo, bevacizumab Sep 23, 2020
Novel Tx Helps Some Advanced Cervical Cancer Patients Three-fourths in small trial obtain disease control or better with antibody-drug conjugate Sep 22, 2020
No Luck for Chemo-Free Tx in First-Line Bladder Cancer Durvalumab alone or with tremelimumab no better than chemotherapy Sep 22, 2020
No Benefit With Anti-PD-L1 Drug in Metastatic TNBC Lack of progression-free, overall survival boost with atezolizumab contrast with prior trial Sep 22, 2020
Adjuvant Anti-CDK Thwarts Early Breast Cancer Recurrence Risk of invasive recurrence declines 25% in patients with high-risk disease Sep 20, 2020
Newly Approved Drug Boosts Survival in Metastatic TNBC Antibody-drug conjugate as third-line option improved survival, response rates Sep 20, 2020
Drug Active in 'Undruggable' KRAS-Mutant NSCLC Responses in a third of patients, disease control rate approaching 90% Sep 20, 2020
CDK4/6 Inhibition Boosts PFS in Endometrial Cancer Median PFS more than doubled by adding palbociclib to endocrine therapy Sep 19, 2020
Another First-Line Combo Succeeds in Advanced RCC Third immunotherapy plus TKI combination tops sunitinib Sep 19, 2020
First-Line Combo Boosts PFS in Untreated Bladder Cancer 'Clinically meaningful' trend in OS with atezolizumab-chemotherapy Oct 03, 2019
New Standard in Third-Line Metastatic CRPC Cabazitaxel tops more anti-androgen in patients with "short-ish" response to abiraterone or enzalutamide Oct 01, 2019
Novel CDK 4/6 Inhibitor Fails in Triple Negative Breast Cancer Misses primary endpoints but has unexpected key benefit Oct 01, 2019
Neoadjuvant Anti-PD-1 Boosts pCR in TNBC Favorable trend toward improved event-free survival in preliminary analysis Sep 30, 2019
Trametinib Tx Shows Promise in Tough-to-Treat LGSOC Targeted drug provokes good response in chemoresistant, low-grade serous ovarian or peritoneal cancer Sep 30, 2019
Data Support 'Best Drug First' in EGFR-Mutant NSCLC Six-month survival gain with osimertinib, adding to PFS, safety advantages Sep 29, 2019
CDK 4/6 Inhibitors Boost OS in Advanced Breast Cancer Abemaciclib, ribociclib should become first-line treatment in HR-positive/HER2-negative disease, expert says Sep 29, 2019
PARP Inhibitors: The Key to a Tx Paradigm Shift in Ovarian Ca? PRIMA and VELIA trial findings advance niraparib and veliparib to the therapeutic front lines Sep 29, 2019
Abemaciclib Offers Hope in HR+/HER2+Breast Cancer Phase II monarcHER trial shows better PFS with abemaciclib-trastuzumab-fulvestrant Sep 29, 2019
First-Line Combo Boosts PFS in Advanced Ovarian Ca Olaparib-bevacizumab maintenance boosts PARP inhibitor benefits beyond BRCA-mutated subgroup Sep 28, 2019
Advanced HCC Trial Misses OS Endpoint But CheckMate 459 researchers tout "encouraging efficacy and favorable safety profile" Sep 28, 2019
Notable OS Gains with Dual Immunotherapy in Advanced NSCLC Secondary analysis of CheckMate 227 brings more good news for nivolumab-ipilimumab combo Sep 28, 2019
Survival Bump with Palbociclib in HR+ Breast Cancer But benefit limited to subgroups; study may have been underpowered Oct 25, 2018
First-Line Anti-PD-1 Ups Survival for Advanced Head/Neck Cancer Pembrolizumab, with or without chemo, tops current standard Oct 24, 2018
Combination Slows Advanced RCC Avelumab-axitinib beneficial, irrespective of PD-L1 status Oct 23, 2018
Prostate RT Ups Overall Survival in Metastatic Disease Benefit limited to men with low disease burden Oct 22, 2018
PI3K Inhibitor Doubles PFS in HR+/HER2- Breast Cancer Benefit limited to patients with PIK3CA mutations Oct 22, 2018
Practice-Changing PARP Inhibitor Study in Ovarian Cancer "Unprecedented" increase in PFS with upfront olaparib maintenance Oct 21, 2018
